Gabriela Hobbs/Massachusetts General Hospital
Sep 4, 2025, 18:00
SOHO 2025: Gabriela Hobbs on Emerging Strategies for Managing Polycythemia Vera and Essential Thrombocythemia
MPN Hub shared on X:
”CONGRESS | SOHO 2025 | PRESENTATION
Gabriela Hobbs, Massachusetts General Hospital News
Discusses novel therapies in development for treatment of Polycythemia Vera, including modulators of hepcidin-ferroportin, bomedemstat, givinostat, and novel JAKis, and in Essential Thrombocythemia, including ropeginterferon, bomedemstat, and CALR-directed agents.
Follow our live feed for more updates.”
Find more slides in the gallery.
All on Hemostasis and Thrombosis from SOHO 2025 featured in Hemostasis Today.
-
Nov 14, 2025, 11:58Marilena Vrana: Can Public-only Blood Collection Systems Meet the Growing Patient Need for PDMs?
-
Nov 14, 2025, 11:48Cedric Hermans Shares the 1st Illustrated Review Dedicated to Hemophilia B
-
Nov 14, 2025, 10:28Valance Washington: Proud to Share Our Lab’s Latest Publication in Platelets Journal
-
Nov 14, 2025, 10:18Sripal Bangalore and Ajay Kirtane on TUXEDO-2 Comparison Focusing on Diabetic Patients
-
Nov 14, 2025, 10:11Ashley Lawrenson on Her Coagulation Journey Using Automation With the HemoCell and HemoHub
-
Nov 14, 2025, 10:05Kingsley Wheaton: A Year Ago, Omni Was an Idea – Today, It’s a Movement!
-
Nov 14, 2025, 09:58Rucha Patil Takes The National DHR-ICMR Gold Award for Best Technology
-
Nov 14, 2025, 09:48Caitlin Raymond on ”The Plasma Chasers”
-
Nov 14, 2025, 09:42Erin VanDyke on Why They Do In-person Site Visits for NBCA Centers of Excellence Designation!